# EDGAR Filing Document

**Accession Number:** 0000315700
**File Stem:** 0000035402-26-004019
**Filing Date:** 2026-6
**Character Count:** 57150
**Document Hash:** 5d5badc1fa9e121ed86751d4096365a8
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000035402-26-004019.hdr.sgml**: 20260626

**ACCESSION NUMBER**: 0000035402-26-004019

**CONFORMED SUBMISSION TYPE**: NPORT-P

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20260430

**FILED AS OF DATE**: 20260626

**DATE AS OF CHANGE**: 20260626

**PERIOD START**: 20260731

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** FIDELITY ADVISOR SERIES VII
- **CENTRAL INDEX KEY:** 0000315700

**ORGANIZATION NAME:**
- **EIN:** 000000000
- **STATE OF INCORPORATION:** MA
- **FISCAL YEAR END:** 0731

**FILING VALUES:**
- **FORM TYPE:** NPORT-P
- **SEC ACT:** 1940 Act
- **SEC FILE NUMBER:** 811-03010
- **FILM NUMBER:** 261126926

**BUSINESS ADDRESS:**
- **STREET 1:** 245 SUMMER STREET
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02210
- **BUSINESS PHONE:** 617-563-7000

**MAIL ADDRESS:**
- **STREET 1:** 245 SUMMER STREET
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02210

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** FIDELITY SECURITIES TRUST
- **DATE OF NAME CHANGE:** 19920703

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** PLYMOUTH SECURITIES TRUST
- **DATE OF NAME CHANGE:** 19911118

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** READY CASH FUND
- **DATE OF NAME CHANGE:** 19880207

## Series and Classes Contracts Data

### Fidelity Advisor Biotechnology Fund (Series ID: S000005321)

| Class ID   | Class Name   | Ticker Symbol   |
|:---|:---|:---|
| C000014519 | Class A      | FBTAX           |
| C000014521 | Class C      | FBTCX           |
| C000014522 | Class M      | FBTTX           |
| C000014523 | Class I      | FBTIX           |
| C000204999 | Class Z      | FIJYX           |

## Nport-Ex

**Consolidated Quarterly Holdings Report**

**for**

**Fidelity Advisor® Biotechnology Fund**

**April 30, 2026**

AFBT-NPRT3-0626

1.800321.122 ---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;**Common Stocks - 97.6%** | &nbsp;&nbsp;**Common Stocks - 97.6%** | &nbsp;&nbsp;**Common Stocks - 97.6%** |
|  | Shares | Value ($)<br>|
| BELGIUM - 0.9%  |  |  |
| Health Care - 0.9% |  |  |
| Pharmaceuticals - 0.9% |  |  |
| UCB SA (b) | 65200 | 17691882 |
| CANADA - 1.3%  |  |  |
| Health Care - 1.3% |  |  |
| Biotechnology - 1.3% |  |  |
| Xenon Pharmaceuticals Inc (b) | 456458 | 25579906 |
| DENMARK - 3.2%  |  |  |
| Health Care - 3.2% |  |  |
| Biotechnology - 3.2% |  |  |
| Ascendis Pharma A/S ADR (b) | 269225 | 61754831 |
| FRANCE - 0.2%  |  |  |
| Health Care - 0.2% |  |  |
| Biotechnology - 0.2% |  |  |
| Inventiva SA ADR (b) | 685400 | 3516101 |
| GERMANY - 0.7%  |  |  |
| Health Care - 0.7% |  |  |
| Biotechnology - 0.7% |  |  |
| Tubulis GmbH (c)(d)(e) | 6300 | 12768320 |
| NETHERLANDS - 4.3%  |  |  |
| Health Care - 4.3% |  |  |
| Biotechnology - 4.3% |  |  |
| Argenx SE ADR (b) | 77200 | 60348784 |
| Newamsterdam Pharma Co NV (b)(f) | 586400 | 16747584 |
| uniQure NV (b) | 223500 | 4458825 |
| TOTAL NETHERLANDS |  | 81555193 |
| UNITED STATES - 87.0%  |  |  |
| Health Care - 87.0% |  |  |
| Biotechnology - 80.0% |  |  |
| AbbVie Inc  | 1335480 | 282213634 |
| Alnylam Pharmaceuticals Inc (b) | 339486 | 105067522 |
| Amgen Inc  | 135103 | 46779414 |
| Annexon Inc (b) | 1661500 | 9753005 |
| Apogee Therapeutics Inc (b) | 452639 | 37519247 |
| Avalo Therapeutics Inc (b)(f) | 358300 | 4801220 |
| Avalyn Pharma Inc  | 5500 | 98999 |
| Biogen Inc (b) | 294100 | 55667248 |
| Celldex Therapeutics Inc (b) | 340152 | 11184198 |
| CG oncology Inc (b) | 157700 | 10524898 |
| Cogent Biosciences Inc (b) | 1834818 | 65668136 |
| Crescent Biopharma Inc (b) | 251090 | 5616883 |
| Crescent Biopharma Inc (b)(e) | 98300 | 2198971 |
| Cyclerion Therapeutics Inc (d)(h) | 88900 | 216027 |
| Cytokinetics Inc (b)(f) | 312871 | 20014358 |
| CytomX Therapeutics Inc (b) | 2229051 | 9406595 |
| Damora Therapeutics Inc (b)(f) | 298142 | 7650324 |
| Dianthus Therapeutics Inc (b)(f) | 730062 | 64099444 |
| Disc Medicine Inc (b) | 142322 | 9386136 |
| Dyne Therapeutics Inc (b)(f) | 482000 | 8459100 |
| First Tracks Biotherapeutics Inc (e) | 192750 | 4485293 |
| First Tracks Biotherapeutics Inc  | 148400 | 3453268 |
| Gilead Sciences Inc  | 788900 | 103219676 |
| Insmed Inc (b) | 489600 | 66747168 |
| Jade Biosciences Inc (b)(f) | 894343 | 21821969 |
| Janux Therapeutics Inc (b) | 320385 | 4603932 |
| Kiniksa Pharmaceuticals International Plc Class A (b) | 417600 | 22458528 |
| Kymera Therapeutics Inc (b) | 231700 | 18783919 |
| MapLight Therapeutics Inc (f) | 202900 | 6466423 |
| Mineralys Therapeutics Inc (b) | 331100 | 8823815 |
| Moderna Inc (b) | 640800 | 29438352 |
| Natera Inc (b) | 89400 | 18430704 |
| Neurogene Inc (b)(f) | 243700 | 6358133 |
| Nuvalent Inc Class A (b) | 412264 | 41341834 |
| Olema Pharmaceuticals Inc (b) | 777200 | 11199452 |
| Oruka Therapeutics Inc (b) | 737386 | 50444576 |
| Praxis Precision Medicines Inc (b) | 67900 | 21648557 |
| Rallybio Corp (d)(e)(g)(h) | 1344817 | 1882744 |
| Relay Therapeutics Inc (b) | 1028900 | 13334544 |
| Revolution Medicines Inc (b) | 299500 | 43163940 |
| Rhythm Pharmaceuticals Inc (b) | 103894 | 8452816 |
| Roivant Sciences Ltd (b) | 776700 | 22159251 |
| Scholar Rock Holding Corp (b)(f) | 118168 | 5507810 |
| Solid Biosciences Inc (b) | 677565 | 4919122 |
| Spyre Therapeutics Inc (b) | 851772 | 63414425 |
| Stoke Therapeutics Inc (b) | 317700 | 10395144 |
| Tango Therapeutics Inc (b) | 403626 | 8726394 |
| Taysha Gene Therapies Inc (b) | 939800 | 6005322 |
| Tectonic Therapeutic Inc (b)(f) | 120995 | 3384230 |
| Tenax Therapeutics Inc (b)(f) | 322600 | 4229286 |
| Travere Therapeutics Inc (b) | 253600 | 10681632 |
| Tyra Biosciences Inc (b) | 354200 | 12308450 |
| Upstream Bio Inc (b) | 691003 | 6343408 |
| Vaxcyte Inc (b) | 763629 | 43710124 |
| Viking Therapeutics Inc (b)(f) | 450187 | 14036831 |
| Viridian Therapeutics Inc (b) | 1782464 | 24027615 |
| X4 Pharmaceuticals Inc (b) | 1341800 | 5461126 |
| Zenas Biopharma Inc (b) | 610924 | 11803052 |
| Zenas Biopharma Inc (e) | 86234 | 1666041 |
|  |  | 1521664265 |
| Pharmaceuticals - 7.0% |  |  |
| Alumis Inc (b) | 330600 | 8162514 |
| Amylyx Pharmaceuticals Inc (b) | 2433200 | 38931200 |
| Axsome Therapeutics Inc (b) | 35800 | 7437450 |
| Crinetics Pharmaceuticals Inc (b) | 544470 | 21114547 |
| Definium Therapeutics Inc (b) | 254100 | 5559708 |
| Edgewise Therapeutics Inc (b) | 144500 | 4473720 |
| Enliven Therapeutics Inc (b)(f) | 328862 | 13558981 |
| Enliven Therapeutics Inc (b)(e) | 73200 | 3018036 |
| Enliven Therapeutics Inc rights (b)(d) | 739725 | 7 |
| MBX Biosciences Inc (b)(f) | 304600 | 9205012 |
| Structure Therapeutics Inc ADR (b) | 481200 | 19945740 |
| VeraDermics Inc  | 10600 | 1049399 |
|  |  | 132456314 |
| TOTAL UNITED STATES |  | 1654120579 |
| <br> **TOTAL COMMON STOCKS**<br> (Cost $948,580,420) |  | <br> **1856986812** |

---

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;**Convertible Corporate Bonds - 0.1%** | &nbsp;&nbsp;**Convertible Corporate Bonds - 0.1%** | &nbsp;&nbsp;**Convertible Corporate Bonds - 0.1%** |
|  | Principal<br> Amount (a)<br>| Value ($)<br>|
| UNITED STATES - 0.1%  |  |  |
| Health Care - 0.1% |  |  |
| Health Care Technology - 0.1% |  |  |
| Wugen Inc 0% 12/31/2199 (d)(e)(i) | 831313 | 865729 |
| Pharmaceuticals - 0.0% |  |  |
| Kartos Therapeutics Inc 3.6% 3/4/2027 (d)(e) | 165791 | 169770 |
| TOTAL UNITED STATES |  | 1035499 |
| <br> **TOTAL CONVERTIBLE CORPORATE BONDS**<br> (Cost $997,104) |  | <br> **1035499** |

---

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;**Convertible Preferred Stocks - 1.6%** | &nbsp;&nbsp;**Convertible Preferred Stocks - 1.6%** | &nbsp;&nbsp;**Convertible Preferred Stocks - 1.6%** |
|  | Shares | Value ($)<br>|
| UNITED STATES - 1.6%  |  |  |
| Health Care - 1.6% |  |  |
| Biotechnology - 1.2% |  |  |
| Bright Peak Therapeutics Inc. Series B (b)(d)(e) | 1920122 | 2188939 |
| Bright Peak Therapeutics Inc. Series C (b)(d)(e) | 873604 | 777508 |
| Cardurion Pharmaceuticals Inc Series B (b)(d)(e) | 331596 | 1830410 |
| Endeavor BioMedicines Inc Series C (b)(d)(e) | 526643 | 3433712 |
| LifeMine Therapeutics Inc Series C (b)(d)(e) | 1950028 | 2301033 |
| Parabilis Medicines Inc Series D (b)(d)(e) | 239281 | 1957319 |
| Parabilis Medicines Inc Series F (d)(e) | 491600 | 3308468 |
| Sonoma Biotherapeutics Inc Series B (b)(d)(e) | 1967762 | 3168097 |
| Sonoma Biotherapeutics Inc Series B1 (b)(d)(e) | 1049456 | 2056934 |
| T-Knife Therapeutics Inc Series B (b)(d)(e) | 1300097 | 910068 |
| Treeline Biosciences Series A (b)(d)(e) | 47600 | 401744 |
|  |  | 22334232 |
| Health Care Technology - 0.1% |  |  |
| Candid Therapeutics Series B (b)(d)(e) | 1500060 | 2100084 |
| Wugen Inc Series B (b)(d)(e) | 580277 | 899429 |
|  |  | 2999513 |
| Pharmaceuticals - 0.3% |  |  |
| Afferent Pharmaceuticals Inc Series C (b)(d)(e) | 1915787 | 19 |
| Kartos Therapeutics Inc Series C (b)(d)(e) | 530692 | 3194766 |
| Mentari Therapeutics Inc Series A (d)(e) | 1457407 | 2331851 |
|  |  | 5526636 |
| TOTAL UNITED STATES |  | 30860381 |
| <br> **TOTAL CONVERTIBLE PREFERRED STOCKS**<br> (Cost $49,300,271) |  | <br> **30860381** |

---

---

| | | | |
|:---|:---|:---|:---|
| &nbsp;&nbsp;**Money Market Funds - 3.0%** | &nbsp;&nbsp;**Money Market Funds - 3.0%** | &nbsp;&nbsp;**Money Market Funds - 3.0%** | &nbsp;&nbsp;**Money Market Funds - 3.0%** |
|  | Yield (%) | Shares | Value ($)<br>|
| Fidelity Cash Central Fund (j) | 3.69 | 14682049 | 14684986 |
| Fidelity Securities Lending Cash Central Fund (j)(k) | 3.69 | 42997056 | 43001356 |
| <br> **TOTAL MONEY MARKET FUNDS**<br> (Cost $57,682,985) |  |  | **57686342** |

---

---

| | |
|:---|:---|
| <br> **TOTAL INVESTMENT IN SECURITIES - 102.3%**<br> (Cost $1,056,560,780)<br>| <br>**1946569034** |
| **NET OTHER ASSETS (LIABILITIES) - (2.3)%**  | **(43457585)** |
| **NET ASSETS - 100.0%** | **1903111449** |

---

**Legend**

(a) Amount is stated in United States dollars unless otherwise noted.

(b) Non-income producing.

(c) Investment is owned by a wholly-owned subsidiary (Subsidiary) that is treated as a corporation for U.S. tax purposes.

(d) Level 3 security.

(e) Restricted securities (including private placements) - Investment in securities not registered under the Securities Act of 1933 (excluding 144A issues). At the end of the period, the value of restricted securities (excluding 144A issues) amounted to $45,146,965 or 2.4% of net assets.

(f) Security or a portion of the security is on loan at period end.

(g) Affiliated company.

(h) Security or a portion of the security purchased on a delayed delivery or when-issued basis.

(i) Coupon rates for floating and adjustable rate securities reflect the rates in effect at period end.

(j) Affiliated fund that is generally available only to investment companies and other accounts managed by Fidelity Investments. The rate quoted is the annualized seven-day yield of the fund at period end. A complete unaudited listing of the fund's holdings as of its most recent quarter end is available upon request. In addition, each Fidelity Central Fund's financial statements are available on the SEC's website or upon request.

(k) Investment made with cash collateral received from securities on loan.

At period end, the value of non-cash collateral for securities on loan amounted to $59,877,408.

---

| | | |
|:---|:---|:---|
| Additional information on each restricted holding is as follows: | Additional information on each restricted holding is as follows: | Additional information on each restricted holding is as follows: |
| Security | Acquisition Date | Acquisition Cost ($)<br>|
| Afferent Pharmaceuticals Inc Series C | 7/1/2015 | 0 |
| Bright Peak Therapeutics Inc. Series B | 5/14/2021 | 7499997 |
| Bright Peak Therapeutics Inc. Series C | 5/7/2024 | 990230 |
| Candid Therapeutics Series B | 8/27/2024 | 1800072 |
| Cardurion Pharmaceuticals Inc Series B | 7/10/2024 | 1624025 |
| Crescent Biopharma Inc | 10/28/2024 - 12/4/2025 | 1305135 |
| Endeavor BioMedicines Inc Series C | 4/22/2024 | 3436135 |
| Enliven Therapeutics Inc | 3/19/2024 | 1024800 |
| First Tracks Biotherapeutics Inc | 3/27/2026 | 2662533 |
| Kartos Therapeutics Inc 3.6% 3/4/2027 | 3/4/2026 | 165791 |
| Kartos Therapeutics Inc Series C | 8/22/2023 | 3000002 |
| LifeMine Therapeutics Inc Series C | 2/15/2022 | 3971408 |
| Mentari Therapeutics Inc Series A | 9/18/2025 | 2000000 |
| Parabilis Medicines Inc Series D | 11/17/2022 | 2575405 |
| Parabilis Medicines Inc Series F | 1/6/2026 | 3030419 |
| Rallybio Corp | 3/2/2026 | 1882744 |
| Sonoma Biotherapeutics Inc Series B | 7/26/2021 | 3888888 |
| Sonoma Biotherapeutics Inc Series B1 | 7/26/2021 | 3111112 |
| T-Knife Therapeutics Inc Series B | 6/30/2021 | 7500000 |
| Treeline Biosciences Series A | 7/30/2021 | 372588 |
| Tubulis GmbH | 12/11/2025 | 2247061 |
| Wugen Inc 0% 12/31/2199 | 6/14/2024 | 831313 |
| Wugen Inc Series B | 7/9/2021 | 4499990 |
| Zenas Biopharma Inc | 10/8/2025 | 1638446 |

---

**Affiliated Central Funds**

Fiscal year to date information regarding the Fund's investments in Fidelity Central Funds, including the ownership percentage, is presented below.

---

| | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| Affiliate  | Value,<br> beginning<br> of period ($) | Purchases ($) | Sales<br> Proceeds ($) | Dividend<br> Income ($) | Realized<br> Gain (loss) ($) | Change in<br> Unrealized<br> appreciation<br> (depreciation) ($) | Value,<br> end<br> of period ($) | <br>Shares,<br> end<br> of period  | % ownership,<br> end<br> of period |
| Fidelity Cash Central Fund | 20544411 | 372456803 | 378315171 | 399284 | (1057) | - | 14684986 | 14682049 | 0.0% |
| Fidelity Securities Lending Cash Central Fund | 99831900 | 489211144 | 546048506 | 539460 | 7584 | (766) | 43001356 | 42997056 | 0.1% |
| Total | 120376311 | 861667947 | 924363677 | 938744 | 6527 | (766) | 57686342 |  |  |

---

Amounts in the dividend income column in the above table include any capital gain distributions from underlying funds.

Amounts in the dividend income column for Fidelity Securities Lending Cash Central Fund represents the income earned on investing cash collateral, less rebates paid to borrowers and any lending agent fees associated with the loan, plus any premium income received for lending certain types of securities.

**Other Affiliated Issuers**

An affiliated company is a company in which the Fund has ownership of at least 5% of the voting securities. Fiscal year to date transactions with companies which are or were affiliates are presented in the table below. Certain corporate actions, such as mergers, are excluded from the amounts in this table if applicable. A dash in the Value end of period ($) and Shares end of period columns means either the issuer is no longer held at period end, or the issuer is held at period end but is no longer an affiliate.

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| Affiliate  | Value,<br> beginning<br> of period ($) | Purchases ($) | Sales<br> Proceeds ($) | Dividend<br> Income ($) | Realized<br> Gain (loss) ($) | Change in<br> Unrealized<br> appreciation<br> (depreciation) ($) | Value,<br> end<br> of period ($) | <br>Shares,<br> end<br> of period  |
| Rallybio Corp | - | 1882744 | - | - | - | - | 1882744 | 1344817 |
| Tenax Therapeutics Inc | - | 4515668 | - | - | - | (286382) | - | - |
| Total | - | 6398412 | - | - | - | (286382) | 1882744 |  |

---

**Investment Valuation**

Investments are valued as of 4:00 p.m. Eastern time on the last calendar day of the period. Securities transactions are accounted for as of trade date. The Board of Trustees (the Board) has designated the Fund's investment adviser as the valuation designee responsible for the fair valuation function and performing fair value determinations as needed. The investment adviser has established a Fair Value Committee (the Committee) to carry out the day-to-day fair valuation responsibilities and has adopted policies and procedures to govern the fair valuation process and the activities of the Committee. In accordance with these fair valuation policies and procedures, which have been approved by the Board, the Fund attempts to obtain prices from one or more third party pricing services or brokers to value its investments. When current market prices, quotations or currency exchange rates are not readily available or reliable, investments will be fair valued in good faith by the Committee, in accordance with the policies and procedures. Factors used in determining fair value vary by investment type and may include market or investment specific events, transaction data, estimated cash flows, and market observations of comparable investments. The frequency that the fair valuation procedures are used cannot be predicted and they may be utilized to a significant extent. The Committee manages the Fund's fair valuation practices and maintains the fair valuation policies and procedures. The Fund's investment adviser reports to the Board information regarding the fair valuation process and related material matters.

The inputs to valuation techniques used to value investments are categorized into a disclosure hierarchy consisting of three levels as shown below:

Level 1 - Unadjusted quoted prices in active markets for identical investments

Level 2 - other significant observable inputs (including quoted prices for similar investments, interest rates, prepayment speeds, etc.)

Level 3 - unobservable inputs (including the Fund's own assumptions based on the best information available)

Valuation techniques used to value investments by major category are as follows:

Equity securities, including restricted securities, for which market quotations are readily available, are valued at the last reported sale price or official closing price as reported by a third party pricing service on the primary market or exchange on which they are traded and are categorized as Level 1 in the hierarchy. In the event there were no sales during the day or closing prices are not available, securities are valued at the last quoted bid price or may be valued using the last available price and are generally categorized as Level 2 in the hierarchy. For any foreign equity securities, when market or security specific events arise, comparisons to the valuation of American Depositary Receipts (ADRs), futures contracts, Exchange-Traded Funds (ETFs) and certain indexes as well as quoted prices for similar securities may be used and would be categorized as Level 2 in the hierarchy. For equity securities, including restricted securities, where observable inputs are limited, assumptions about market activity and risk are used and these securities may be categorized as Level 3 in the hierarchy.

Securities, including private placements or other restricted securities, for which observable inputs are not available are valued using alternate valuation approaches, including the market approach, the income approach and cost approach, and are categorized as Level 3 in the hierarchy. The market approach considers factors including the price of recent investments in the same or a similar security or financial metrics of comparable securities. The income approach considers factors including expected future cash flows, security specific risks and corresponding discount rates. The cost approach considers factors including the value of the security's underlying assets and liabilities.

Debt securities, including restricted securities, are valued based on evaluated prices received from third party pricing services or from brokers who make markets in such securities. Convertible Corporate Bonds are valued by pricing services who utilize matrix pricing which considers yield or price of bonds of comparable quality, coupon, maturity and type or by broker-supplied prices. When independent prices are unavailable or unreliable, debt securities may be valued utilizing pricing methodologies which consider similar factors that would be used by third party pricing services. Debt securities are generally categorized as Level 2 in the hierarchy but may be Level 3 depending on the circumstances.

Investments in any open-end mutual funds are valued at their closing net asset value (NAV) each business day and are categorized as Level 1 in the hierarchy.

Changes in valuation techniques may result in transfers in or out of an assigned level within the disclosure hierarchy.

For additional information on the Fund's significant accounting policies, please refer to the Fund's most recent semiannual or annual shareholder report.

*The fund's consolidated schedule of investments as of the date on the cover of this report has not been audited. This report is provided for the general information of the fund's shareholders. For more information regarding the fund and its holdings, please see the fund's most recent prospectus and annual report.*

*Third party trademarks and service marks are the property of their respective owners. All other trademarks and service marks are the property of FMR LLC or an affiliate.*

## Form NPORT-P: Monthly Portfolio Investments Report

### NPORT-P: Part A: General Information

**Item A.1. Information about the Registrant.**

- **a. Name of Registrant:** Fidelity Advisor Series VII

- **b. Investment Company Act file number:** 811-03010

- **c. CIK number of Registrant:** 0000315700

- **d. LEI of Registrant:** PM3JTBFBEM0RCCY2GO89

- **e. Address and telephone number of Registrant.**

  - **Street Address 1:** 245 Summer Street

  - **City:** Boston

  - **State:** MA

  - **Foreign country:** US

  - **Zip / Postal Code:** 02210

  - **Telephone number:** 1-800-FIDELITY

**Item A.2. Information about the Series.**

- **a. Name of Series:** Fidelity Advisor Biotechnology Fund

- **b. EDGAR series identifier (if any):** S000005321

- **c. LEI of Series:** C7UWI9NYV6ZT61IPLX72

**Item A.3. Reporting period.**

- **a. Date of fiscal year-end:** 2026-07-31

- **b. Date as of which information is reported:** 2026-04-30

**Item A.4. Final filing**

Does the Fund anticipate that this will be its final filing on Form N-PORT? **No**

### Fund Information

**Total Assets:** $1954607807.00

**Total Liabilities:** $51229886.52

**Net Assets:** $1903377920.48

**Delayed Delivery Securities:** $2091961.06

**Monthly Return Information**

| Class               | Month 1 Return (%)   | Month 2 Return (%)   | Month 3 Return (%)   |
|:---|:---|:---|:---|
| Class ID C000204999 | 2.19%                | -1.26%               | 2.08%                |
| Class ID C000014519 | 2.16%                | -1.29%               | 2.06%                |
| Class ID C000014522 | 2.15%                | -1.31%               | 2.02%                |
| Class ID C000014521 | 2.10%                | -1.35%               | 1.98%                |
| Class ID C000014523 | 2.20%                | -1.29%               | 2.09%                |

**Monthly Gains & Losses**

| Period   | Net Realized Gain/Loss   | Net Unrealized Appreciation/Depreciation   |
|:---|:---|:---|
| Month 1  | $22958987.25             | $18345423.61                               |
| Month 2  | $21233152.28             | $-45315249.93                              |
| Month 3  | $15623274.49             | $18781919.42                               |

### Schedule of Portfolio Investments

| Name                                      | Title                                           | Identifiers                                   | Payoff Profile   | Asset Category   | Issuer Category   | Country   |   Balance | Units   | Value (USD)   | % of Net Assets   | Maturity Date   | Coupon Type   | Annualized Rate (%)   | Restricted?   |   Fair Value Level | Lending Status   |
|:---|:---|:---|:---|:---|:---|:---|---:|:---|:---|:---|:---|:---|:---|:---|---:|:---|
| UPSTREAM BIO INC                          | UPSTREAM BIO INC                                | CUSIP: 91678A107<br>LEI: N/A                  | Long             | EC               | CORP              | US        |    691003 | NS      | $6343407.54   | 0.33%             |  |  |  | No            |                  1 | On Loan: No      |
| T-KNIFE THERAPEUTICS INC                  | T-KNIFE THERAPEUTICS INC SER B PC PP            | CUSIP: N/A<br>LEI: N/A                        | Long             | EP               | CORP              | US        |   1300097 | NS      | $910067.90    | 0.05%             |  |  |  | Yes           |                  3 | On Loan: No      |
| DIANTHUS THERAPEUTICS INC                 | DIANTHUS THERAPEUTICS INC                       | CUSIP: 252828108<br>LEI: 549300Z3N6ODPCOFC890 | Long             | EC               | CORP              | US        |    730062 | NS      | $64099443.60  | 3.37%             |  |  |  | No            |                  1 | On Loan: —       |
| FABIO TUB HOLDINGS LLC                    | FABIO TUB HOLDINGS LLC PP                       | CUSIP: N/A<br>LEI: N/A                        | Long             | EC               | CORP              | DE        |      6300 | NS      | $12768320.30  | 0.67%             |  |  |  | Yes           |                  3 | On Loan: No      |
| CRESCENT BIOPHARMA INC                    | CRESCENT BIOPHARMA INC                          | CUSIP: N/A<br>LEI: 549300TZ84FFU2J2J459       | Long             | EC               | CORP              | KY        |    251090 | NS      | $5616883.30   | 0.30%             |  |  |  | No            |                  1 | On Loan: No      |
| NEUROGENE INC                             | NEUROGENE INC                                   | CUSIP: 64135M105<br>LEI: 529900A7VIY892SZVW73 | Long             | EC               | CORP              | US        |    243700 | NS      | $6358133.00   | 0.33%             |  |  |  | No            |                  1 | On Loan: —       |
| AMGEN INC                                 | AMGEN INC                                       | CUSIP: 031162100<br>LEI: 62QBXGPJ34PQ72Z12S66 | Long             | EC               | CORP              | US        |    135103 | NS      | $46779413.75  | 2.46%             |  |  |  | No            |                  1 | On Loan: No      |
| PRAXIS PRECISION MEDICINES INC.           | PRAXIS PRECISION MEDICINES INC                  | CUSIP: 74006W207<br>LEI: N/A                  | Long             | EC               | CORP              | US        |     67900 | NS      | $21648557.00  | 1.14%             |  |  |  | No            |                  1 | On Loan: No      |
| AXSOME THERAPEUTICS INC                   | AXSOME THERAPEUTICS INC                         | CUSIP: 05464T104<br>LEI: 549300EXGR0XLRJEIB95 | Long             | EC               | CORP              | US        |     35800 | NS      | $7437450.00   | 0.39%             |  |  |  | No            |                  1 | On Loan: No      |
| ABBVIE INC                                | ABBVIE INC                                      | CUSIP: 00287Y109<br>LEI: FR5LCKFTG8054YNNRU85 | Long             | EC               | CORP              | US        |   1335480 | NS      | $282213633.60 | 14.83%            |  |  |  | No            |                  1 | On Loan: No      |
| X4 PHARMACEUTICALS INC                    | X4 PHARMACEUTICALS INC                          | CUSIP: 98420X202<br>LEI: 549300R0UFVPXWP86U94 | Long             | EC               | CORP              | US        |   1341800 | NS      | $5461126.00   | 0.29%             |  |  |  | No            |                  1 | On Loan: No      |
| SONOMA BIOTHERAPEUTICS INC                | SONOMA BIOTHERAPEUTICS INC SER B1 PFD PP        | CUSIP: N/A<br>LEI: N/A                        | Long             | EP               | CORP              | US        |   1049456 | NS      | $2056933.76   | 0.11%             |  |  |  | Yes           |                  3 | On Loan: No      |
| AFFERENT PHARMA                           | AFFERENT PHARMACEUTICALS INC SER C PC PP        | CUSIP: N/A<br>LEI: N/A                        | Long             | EP               | CORP              | US        |   1915787 | NS      | $19.16        | 0.00%             |  |  |  | Yes           |                  3 | On Loan: No      |
| ENLIVEN THERAPEUTICS INC                  | ENLIVEN THERAPEUTICS INC CVR (NON-TRADABLE)     | CUSIP: N/A<br>LEI: N/A                        | Long             | EC               | CORP              | US        |    739725 | NS      | $7.40         | 0.00%             |  |  |  | No            |                  3 | On Loan: No      |
| CRINETICS PHARMACEUTICALS INC             | CRINETICS PHARMACEUTICALS INC                   | CUSIP: 22663K107<br>LEI: 549300Q1CNFXK5P31D28 | Long             | EC               | CORP              | US        |    544470 | NS      | $21114546.60  | 1.11%             |  |  |  | No            |                  1 | On Loan: No      |
| SONOMA BIOTHERAPEUTICS INC                | SONOMA BIOTHERAPEUTICS INC SER B PFD PP         | CUSIP: N/A<br>LEI: N/A                        | Long             | EP               | CORP              | US        |   1967762 | NS      | $3168096.82   | 0.17%             |  |  |  | Yes           |                  3 | On Loan: No      |
| NEWAMSTERDAM PHARMA COMPANY NV            | NEWAMSTERDAM PHARMA COMPANY NV                  | CUSIP: N/A<br>LEI: 984500B6549TF6E14D36       | Long             | EC               | CORP              | NL        |    586400 | NS      | $16747584.00  | 0.88%             |  |  |  | No            |                  1 | On Loan: —       |
| ENDEAVOR BIOMEDICINES INC                 | ENDEAVOR BIOMEDICINES INC SERIES C PC PP        | CUSIP: N/A<br>LEI: N/A                        | Long             | EP               | CORP              | US        |    526643 | NS      | $3433712.36   | 0.18%             |  |  |  | Yes           |                  3 | On Loan: No      |
| DAMORA THERAPEUTICS INC                   | DAMORA THERAPEUTICS INC                         | CUSIP: 36322Q206<br>LEI: N/A                  | Long             | EC               | CORP              | US        |    298142 | NS      | $7650323.72   | 0.40%             |  |  |  | No            |                  1 | On Loan: —       |
| CYCLERION THERAPEUTICS INC                | KORSANA BIOSCIENCES PIPE                        | CUSIP: N/A<br>LEI: N/A                        | Long             | EC               | CORP              | US        |     88900 | NS      | $216027.00    | 0.01%             |  |  |  | Yes           |                  3 | On Loan: No      |
| CRESCENT BIOPHARMA INC                    | CRESCENT BIOPHARMA INC PIPE                     | CUSIP: N/A<br>LEI: 549300TZ84FFU2J2J459       | Long             | EC               | CORP              | KY        |     98300 | NS      | $2198971.00   | 0.12%             |  |  |  | Yes           |                  1 | On Loan: No      |
| DISC MEDICINE INC                         | DISC MEDICINE INC                               | CUSIP: 254604101<br>LEI: N/A                  | Long             | EC               | CORP              | US        |    142322 | NS      | $9386135.90   | 0.49%             |  |  |  | No            |                  1 | On Loan: No      |
| AMYLYX PHARMACEUTICALS INC                | AMYLYX PHARMACEUTICALS INC                      | CUSIP: 03237H101<br>LEI: N/A                  | Long             | EC               | CORP              | US        |   2433200 | NS      | $38931200.00  | 2.05%             |  |  |  | No            |                  1 | On Loan: No      |
| BIOGEN INC                                | BIOGEN INC                                      | CUSIP: 09062X103<br>LEI: W8J5WZB5IY3K0NDQT671 | Long             | EC               | CORP              | US        |    294100 | NS      | $55667248.00  | 2.92%             |  |  |  | No            |                  1 | On Loan: No      |
| WUGEN INC                                 | WUGEN INC SER B PC PP                           | CUSIP: N/A<br>LEI: N/A                        | Long             | EP               | CORP              | US        |    580277 | NS      | $899429.35    | 0.05%             |  |  |  | Yes           |                  3 | On Loan: No      |
| CARDURION PHARMACEUTICALS INC             | CARDURION PHARMACEUTICALS INC SER B PC PP       | CUSIP: N/A<br>LEI: N/A                        | Long             | EP               | CORP              | US        |    331596 | NS      | $1830409.92   | 0.10%             |  |  |  | Yes           |                  3 | On Loan: No      |
| KARTOS THERAPEUTICS INC                   | KARTOS THERAPEUTICS INC SERIES C PC PP          | CUSIP: N/A<br>LEI: N/A                        | Long             | EP               | CORP              | US        |    530692 | NS      | $3194765.84   | 0.17%             |  |  |  | Yes           |                  3 | On Loan: No      |
| ORUKA THERAPEUTICS INC                    | ORUKA THERAPEUTICS INC                          | CUSIP: 687604108<br>LEI: 529900TG7O4ESUDMGI54 | Long             | EC               | CORP              | US        |    737386 | NS      | $50444576.26  | 2.65%             |  |  |  | No            |                  1 | On Loan: No      |
| SCHOLAR ROCK HOLDING CORP                 | SCHOLAR ROCK HOLDING CORP                       | CUSIP: 80706P103<br>LEI: 549300Z1FLPGL4OWJ459 | Long             | EC               | CORP              | US        |    118168 | NS      | $5507810.48   | 0.29%             |  |  |  | No            |                  1 | On Loan: —       |
| MBX BIOSCIENCES INC                       | MBX BIOSCIENCES INC                             | CUSIP: 55287L101<br>LEI: N/A                  | Long             | EC               | CORP              | US        |    304600 | NS      | $9205012.00   | 0.48%             |  |  |  | No            |                  1 | On Loan: —       |
| ALUMIS INC                                | ALUMIS INC                                      | CUSIP: 022307102<br>LEI: N/A                  | Long             | EC               | CORP              | US        |    330600 | NS      | $8162514.00   | 0.43%             |  |  |  | No            |                  1 | On Loan: No      |
| LIFEMINE THERAPEUTICS INC                 | LIFEMINE THERAPEUTICS INC SER C PP              | CUSIP: N/A<br>LEI: N/A                        | Long             | EP               | CORP              | US        |   1950028 | NS      | $2301033.04   | 0.12%             |  |  |  | Yes           |                  3 | On Loan: No      |
| SOLID BIOSCIENCES INC                     | SOLID BIOSCIENCES INC                           | CUSIP: 83422E204<br>LEI: N/A                  | Long             | EC               | CORP              | US        |    677565 | NS      | $4919121.90   | 0.26%             |  |  |  | No            |                  1 | On Loan: No      |
| ARGENX SE                                 | ARGENX SE SPONSORED ADR                         | CUSIP: 04016X101<br>LEI: 7245009C5FZE6G9ODQ71 | Long             | EC               | CORP              | NL        |     77200 | NS      | $60348784.00  | 3.17%             |  |  |  | No            |                  1 | On Loan: —       |
| FIRST TRACKS BIOTHERAPEUTICS INC          | FIRST TRACKS BIOTHERAPEUTICS INC PIPE           | CUSIP: N/A<br>LEI: 529900CGIGKN4R5RO925       | Long             | EC               | CORP              | US        |    192750 | NS      | $4485292.50   | 0.24%             |  |  |  | Yes           |                  1 | On Loan: No      |
| PARABILIS MEDICINES INC                   | PARABILIS MEDICINES INC SER F PC PP             | CUSIP: N/A<br>LEI: N/A                        | Long             | EP               | CORP              | US        |    491600 | NS      | $3308468.00   | 0.17%             |  |  |  | Yes           |                  3 | On Loan: No      |
| DEFINIUM THERAPEUTICS INC                 | DEFINIUM THERAPEUTICS INC                       | CUSIP: 24477V105<br>LEI: 529900UG3DGE202N5D44 | Long             | EC               | CORP              | CA        |    254100 | NS      | $5559708.00   | 0.29%             |  |  |  | No            |                  1 | On Loan: No      |
| KINIKSA PHARMACEUTICALS INTERNATIONAL PLC | KINIKSA PHARMACEUTICALS INTERNATIONAL PLC       | CUSIP: N/A<br>LEI: N/A                        | Long             | EC               | CORP              | GB        |    417600 | NS      | $22458528.00  | 1.18%             |  |  |  | No            |                  1 | On Loan: No      |
| EDGEWISE THERAPEUTICS INC                 | EDGEWISE THERAPEUTICS INC                       | CUSIP: 28036F105<br>LEI: N/A                  | Long             | EC               | CORP              | US        |    144500 | NS      | $4473720.00   | 0.24%             |  |  |  | No            |                  1 | On Loan: No      |
| MENTARI THERAPEUTICS INC                  | MENTARI THERAPEUTICS INC SER A PC PP            | CUSIP: N/A<br>LEI: N/A                        | Long             | EP               | CORP              | US        |   1457407 | NS      | $2331851.20   | 0.12%             |  |  |  | Yes           |                  3 | On Loan: No      |
| TECTONIC THERAPEUTIC INC                  | TECTONIC THERAPEUTIC INC                        | CUSIP: 878972108<br>LEI: N/A                  | Long             | EC               | CORP              | US        |    120995 | NS      | $3384230.15   | 0.18%             |  |  |  | No            |                  1 | On Loan: —       |
| MAPLIGHT THERAPEUTICS INC                 | MAPLIGHT THERAPEUTICS INC                       | CUSIP: 56565P103<br>LEI: N/A                  | Long             | EC               | CORP              | US        |    202900 | NS      | $6466423.00   | 0.34%             |  |  |  | No            |                  1 | On Loan: —       |
| TYRA BIOSCIENCES INC                      | TYRA BIOSCIENCES INC                            | CUSIP: 90240B106<br>LEI: N/A                  | Long             | EC               | CORP              | US        |    354200 | NS      | $12308450.00  | 0.65%             |  |  |  | No            |                  1 | On Loan: No      |
| UNIQURE N.V.                              | UNIQURE N.V.                                    | CUSIP: N/A<br>LEI: 724500RPCTZLFYJZ3S98       | Long             | EC               | CORP              | NL        |    223500 | NS      | $4458825.00   | 0.23%             |  |  |  | No            |                  1 | On Loan: No      |
| JANUX THERAPEUTICS INC                    | JANUX THERAPEUTICS INC                          | CUSIP: 47103J105<br>LEI: N/A                  | Long             | EC               | CORP              | US        |    320385 | NS      | $4603932.45   | 0.24%             |  |  |  | No            |                  1 | On Loan: No      |
| ENLIVEN THERAPEUTICS INC                  | ENLIVEN THERAPEUTICS INC                        | CUSIP: 29337E102<br>LEI: N/A                  | Long             | EC               | CORP              | US        |    328862 | NS      | $13558980.26  | 0.71%             |  |  |  | No            |                  1 | On Loan: —       |
| RELAY THERAPEUTICS INC                    | RELAY THERAPEUTICS INC                          | CUSIP: 75943R102<br>LEI: N/A                  | Long             | EC               | CORP              | US        |   1028900 | NS      | $13334544.00  | 0.70%             |  |  |  | No            |                  1 | On Loan: No      |
| INVENTIVA SA                              | INVENTIVA SA UNSPON ADR                         | CUSIP: 46124U107<br>LEI: 969500I9Y690B3FZW590 | Long             | EC               | CORP              | FR        |    685400 | NS      | $3516102.00   | 0.18%             |  |  |  | No            |                  1 | On Loan: No      |
| REVOLUTION MEDICINES INC                  | REVOLUTION MEDICINES INC                        | CUSIP: 76155X100<br>LEI: 549300JU3X0LBCQ65892 | Long             | EC               | CORP              | US        |    299500 | NS      | $43163940.00  | 2.27%             |  |  |  | No            |                  1 | On Loan: No      |
| VAXCYTE INC                               | VAXCYTE INC                                     | CUSIP: 92243G108<br>LEI: 254900M7NMHTGASX8D95 | Long             | EC               | CORP              | US        |    763629 | NS      | $43710123.96  | 2.30%             |  |  |  | No            |                  1 | On Loan: No      |
| MODERNA INC                               | MODERNA INC                                     | CUSIP: 60770K107<br>LEI: 549300EI6OKH5K5Q2G38 | Long             | EC               | CORP              | US        |    640800 | NS      | $29438352.00  | 1.55%             |  |  |  | No            |                  1 | On Loan: No      |
| VIRIDIAN THERAPEUTICS INC                 | VIRIDIAN THERAPEUTICS INC                       | CUSIP: 92790C104<br>LEI: 549300C775BNYF550E70 | Long             | EC               | CORP              | US        |   1782464 | NS      | $24027614.72  | 1.26%             |  |  |  | No            |                  1 | On Loan: No      |
| TANGO THERAPEUTICS INC                    | TANGO THERAPEUTICS INC                          | CUSIP: 87583X109<br>LEI: N/A                  | Long             | EC               | CORP              | US        |    403626 | NS      | $8726394.12   | 0.46%             |  |  |  | No            |                  1 | On Loan: No      |
| SPYRE THERAPEUTICS INC                    | SPYRE THERAPEUTICS INC                          | CUSIP: 00773J202<br>LEI: 52990017AIJPRH3HQH40 | Long             | EC               | CORP              | US        |    851772 | NS      | $63414425.40  | 3.33%             |  |  |  | No            |                  1 | On Loan: No      |
| MINERALYS THERAPEUTICS INC                | MINERALYS THERAPEUTICS INC                      | CUSIP: 603170101<br>LEI: N/A                  | Long             | EC               | CORP              | US        |    331100 | NS      | $8823815.00   | 0.46%             |  |  |  | No            |                  1 | On Loan: No      |
| STRUCTURE THERAPEUTICS INC                | STRUCTURE THERAPEUTICS INC ADR                  | CUSIP: 86366E106<br>LEI: N/A                  | Long             | EC               | CORP              | KY        |    481200 | NS      | $19945740.00  | 1.05%             |  |  |  | No            |                  1 | On Loan: No      |
| ANNEXON INC                               | ANNEXON INC                                     | CUSIP: 03589W102<br>LEI: N/A                  | Long             | EC               | CORP              | US        |   1661500 | NS      | $9753005.00   | 0.51%             |  |  |  | No            |                  1 | On Loan: No      |
| ROIVANT SCIENCES LTD                      | ROIVANT SCIENCES LTD                            | CUSIP: N/A<br>LEI: 549300DL466NY5J6U724       | Long             | EC               | CORP              | BM        |    776700 | NS      | $22159251.00  | 1.16%             |  |  |  | No            |                  1 | On Loan: No      |
| JADE BIOSCIENCES INC                      | JADE BIOSCIENCES INC                            | CUSIP: 008064206<br>LEI: N/A                  | Long             | EC               | CORP              | US        |    894343 | NS      | $21821969.20  | 1.15%             |  |  |  | No            |                  1 | On Loan: —       |
| PARABILIS MEDICINES INC                   | PARABILIS MEDICINES INC SER D PC PP             | CUSIP: N/A<br>LEI: N/A                        | Long             | EP               | CORP              | US        |    239281 | NS      | $1957318.58   | 0.10%             |  |  |  | Yes           |                  3 | On Loan: No      |
| RALLYBIO CORP                             | CANDID THERAPEUTICS PIPE                        | CUSIP: N/A<br>LEI: 254900OR8EZO4FXWJY12       | Long             | EC               | CORP              | US        |   1344817 | NS      | $1882743.80   | 0.10%             |  |  |  | Yes           |                  3 | On Loan: No      |
| CYTOKINETICS INC                          | CYTOKINETICS INC                                | CUSIP: 23282W605<br>LEI: 549300BE5DY1HW7IHA64 | Long             | EC               | CORP              | US        |    312871 | NS      | $20014357.87  | 1.05%             |  |  |  | No            |                  1 | On Loan: —       |
| TREELINE BIOSCIENCES                      | TREELINE BIOSCIENCES SERIES A PC PP             | CUSIP: N/A<br>LEI: N/A                        | Long             | EP               | CORP              | US        |     47600 | NS      | $401744.00    | 0.02%             |  |  |  | Yes           |                  3 | On Loan: No      |
| Fidelity Revere Street Trust              | Fidelity Cash Central Fund                      | CUSIP: 31635A105<br>LEI: 549300BDV45LJNXBZC55 | Long             | STIV             | RF                | US        |  14682049 | NS      | $14684985.85  | 0.77%             |  |  |  | No            |                  1 | On Loan: No      |
| ASCENDIS PHARMA A/S                       | ASCENDIS PHARMA AS                              | CUSIP: N/A<br>LEI: 549300B66JN3W3J8GH73       | Long             | EC               | CORP              | DK        |    269225 | NS      | $61754830.50  | 3.24%             |  |  |  | No            |                  1 | On Loan: No      |
| NATERA INC                                | NATERA INC                                      | CUSIP: 632307104<br>LEI: 529900CQ3OZ0A0VYVU59 | Long             | EC               | CORP              | US        |     89400 | NS      | $18430704.00  | 0.97%             |  |  |  | No            |                  1 | On Loan: No      |
| CYTOMX THERAPEUTICS INC                   | CYTOMX THERAPEUTICS INC                         | CUSIP: 23284F105<br>LEI: 5493004VW2FW0QLL3345 | Long             | EC               | CORP              | US        |   2229051 | NS      | $9406595.22   | 0.49%             |  |  |  | No            |                  1 | On Loan: No      |
| CANDID THERAPEUTICS                       | CANDID THERAPEUTICS INC SER B PC PP             | CUSIP: N/A<br>LEI: N/A                        | Long             | EP               | CORP              | US        |   1500060 | NS      | $2100084.00   | 0.11%             |  |  |  | Yes           |                  3 | On Loan: No      |
| FIRST TRACKS BIOTHERAPEUTICS INC          | FIRST TRACKS BIOTHERAPEUTICS INC                | CUSIP: 337185102<br>LEI: 529900CGIGKN4R5RO925 | Long             | EC               | CORP              | US        |    148400 | NS      | $3453268.00   | 0.18%             |  |  |  | No            |                  1 | On Loan: No      |
| ZENAS BIOPHARMA INC                       | ZENAS BIOPHARMA INC PIPE                        | CUSIP: N/A<br>LEI: N/A                        | Long             | EC               | CORP              | US        |     86234 | NS      | $1666040.88   | 0.09%             |  |  |  | Yes           |                  1 | On Loan: No      |
| VERADERMICS INC                           | VERADERMICS INC                                 | CUSIP: 922967104<br>LEI: N/A                  | Long             | EC               | CORP              | US        |      7400 | NS      | $732600.00    | 0.04%             |  |  |  | No            |                  1 | On Loan: No      |
| STOKE THERAPEUTICS INC                    | STOKE THERAPEUTICS INC                          | CUSIP: 86150R107<br>LEI: 549300RD25SS2DIJHJ67 | Long             | EC               | CORP              | US        |    317700 | NS      | $10395144.00  | 0.55%             |  |  |  | No            |                  1 | On Loan: No      |
| UCB SA                                    | UCB SA                                          | CUSIP: N/A<br>LEI: 2138008J191VLSGY5A09       | Long             | EC               | CORP              | BE        |     65200 | NS      | $17691881.83  | 0.93%             |  |  |  | No            |                  1 | On Loan: No      |
| RHYTHM PHARMACEUTICALS INC                | RHYTHM PHARMACEUTICALS INC                      | CUSIP: 76243J105<br>LEI: 529900JPNWXQ8DPLA551 | Long             | EC               | CORP              | US        |    117433 | NS      | $9554348.88   | 0.50%             |  |  |  | No            |                  1 | On Loan: No      |
| DYNE THERAPEUTICS INC                     | DYNE THERAPEUTICS INC                           | CUSIP: 26818M108<br>LEI: N/A                  | Long             | EC               | CORP              | US        |    482000 | NS      | $8459100.00   | 0.44%             |  |  |  | No            |                  1 | On Loan: —       |
| KARTOS THERAPEUTICS INC                   | KARTOS THERAPUTIC, INC. CONV 3.6% 03/04/2026 PP | CUSIP: N/A<br>LEI: N/A                        | Long             | DBT              | CORP              | US        |    165791 | PA      | $169769.94    | 0.01%             | 2027-03-04      | Fixed         | 0.04%                 | Yes           |                  3 | On Loan: No      |
| ALNYLAM PHARMACEUTICALS INC               | ALNYLAM PHARMACEUTICALS INC                     | CUSIP: 02043Q107<br>LEI: 529900S3ZI14OWRJII50 | Long             | EC               | CORP              | US        |    339486 | NS      | $105067522.14 | 5.52%             |  |  |  | No            |                  1 | On Loan: No      |
| ZENAS BIOPHARMA INC                       | ZENAS BIOPHARMA INC                             | CUSIP: 98937L105<br>LEI: N/A                  | Long             | EC               | CORP              | US        |    610924 | NS      | $11803051.68  | 0.62%             |  |  |  | No            |                  1 | On Loan: No      |
| Fidelity Revere Street Trust              | Fidelity Securities Lending Cash Central Fund   | CUSIP: 31635A303<br>LEI: 549300BDV45LJNXBZC55 | Long             | STIV             | RF                | US        |  47773970 | NS      | $47778747.22  | 2.51%             |  |  |  | No            |                  1 | On Loan: No      |
| KYMERA THERAPEUTICS INC                   | KYMERA THERAPEUTICS INC                         | CUSIP: 501575104<br>LEI: N/A                  | Long             | EC               | CORP              | US        |    231700 | NS      | $18783919.00  | 0.99%             |  |  |  | No            |                  1 | On Loan: No      |
| XENON PHARMACEUTICALS INC                 | XENON PHARMACEUTICALS INC                       | CUSIP: 98420N105<br>LEI: 549300XV44Q9Z1MIPQ03 | Long             | EC               | CORP              | CA        |    456458 | NS      | $25579906.32  | 1.34%             |  |  |  | No            |                  1 | On Loan: No      |
| TRAVERE THERAPEUTICS INC                  | TRAVERE THERAPEUTICS INC                        | CUSIP: 89422G107<br>LEI: N/A                  | Long             | EC               | CORP              | US        |    253600 | NS      | $10681632.00  | 0.56%             |  |  |  | No            |                  1 | On Loan: No      |
| OLEMA PHARMACEUTICALS INC                 | OLEMA PHARMACEUTICALS INC                       | CUSIP: 68062P106<br>LEI: N/A                  | Long             | EC               | CORP              | US        |    777200 | NS      | $11199452.00  | 0.59%             |  |  |  | No            |                  1 | On Loan: No      |
| WUGEN INC                                 | WUGEN INC CONV 0% 12/31/2199 P/P                | CUSIP: N/A<br>LEI: N/A                        | Long             | DBT              | CORP              | US        |    831313 | PA      | $865729.36    | 0.05%             | 2199-12-31      | Variable      | 0.00%                 | Yes           |                  3 | On Loan: No      |
| BRIGHT PEAK THERAPEUTICS INC.             | BRIGHT PEAK THERAPEUTICS SER C PC PP            | CUSIP: N/A<br>LEI: N/A                        | Long             | EP               | CORP              | US        |    873604 | NS      | $777507.56    | 0.04%             |  |  |  | Yes           |                  3 | On Loan: No      |
| COGENT BIOSCIENCES INC                    | COGENT BIOSCIENCES INC                          | CUSIP: 19240Q201<br>LEI: N/A                  | Long             | EC               | CORP              | US        |   1834818 | NS      | $65668136.22  | 3.45%             |  |  |  | No            |                  1 | On Loan: No      |
| CG ONCOLOGY INC                           | CG ONCOLOGY INC                                 | CUSIP: 156944100<br>LEI: N/A                  | Long             | EC               | CORP              | US        |    157700 | NS      | $10524898.00  | 0.55%             |  |  |  | No            |                  1 | On Loan: No      |
| AVALO THERAPEUTICS INC                    | AVALO THERAPEUTICS INC                          | CUSIP: 05338F306<br>LEI: 549300GPK6FPJ3X8SZ39 | Long             | EC               | CORP              | US        |    358300 | NS      | $4801220.00   | 0.25%             |  |  |  | No            |                  1 | On Loan: —       |
| INSMED INC                                | INSMED INC                                      | CUSIP: 457669307<br>LEI: 529900Q55QAG41CCAC11 | Long             | EC               | CORP              | US        |    489600 | NS      | $66747168.00  | 3.51%             |  |  |  | No            |                  1 | On Loan: No      |
| TENAX THERAPEUTICS INC                    | TENAX THERAPEUTICS INC                          | CUSIP: 88032L605<br>LEI: 549300J03O6B1IJ2B606 | Long             | EC               | CORP              | US        |    322600 | NS      | $4229286.00   | 0.22%             |  |  |  | No            |                  1 | On Loan: —       |
| GILEAD SCIENCES INC                       | GILEAD SCIENCES INC                             | CUSIP: 375558103<br>LEI: 549300WTZWR07K8MNV44 | Long             | EC               | CORP              | US        |    788900 | NS      | $103219676.00 | 5.42%             |  |  |  | No            |                  1 | On Loan: No      |
| TAYSHA GENE THERAPIES INC                 | TAYSHA GENE THERAPIES INC                       | CUSIP: 877619106<br>LEI: N/A                  | Long             | EC               | CORP              | US        |    939800 | NS      | $6005322.00   | 0.32%             |  |  |  | No            |                  1 | On Loan: No      |
| VIKING THERAPEUTICS INC                   | VIKING THERAPEUTICS INC                         | CUSIP: 92686J106<br>LEI: 529900IVC72YPFA25M37 | Long             | EC               | CORP              | US        |    450187 | NS      | $14036830.66  | 0.74%             |  |  |  | No            |                  1 | On Loan: —       |
| APOGEE THERAPEUTICS INC                   | APOGEE THERAPEUTICS INC                         | CUSIP: 03770N101<br>LEI: N/A                  | Long             | EC               | CORP              | US        |    452639 | NS      | $37519246.71  | 1.97%             |  |  |  | No            |                  1 | On Loan: No      |
| ENLIVEN THERAPEUTICS INC                  | ENLIVEN THERAPEUTICS INC PIPE                   | CUSIP: N/A<br>LEI: N/A                        | Long             | EC               | CORP              | US        |     73200 | NS      | $3018036.00   | 0.16%             |  |  |  | Yes           |                  1 | On Loan: No      |
| CELLDEX THERAPEUTICS INC                  | CELLDEX THERAPEUTICS INC                        | CUSIP: 15117B202<br>LEI: 529900F018DMYWH38923 | Long             | EC               | CORP              | US        |    340152 | NS      | $11184197.76  | 0.59%             |  |  |  | No            |                  1 | On Loan: No      |
| BRIGHT PEAK THERAPEUTICS INC.             | BRIGHT PEAK THERAPEUTICS SER B PC PP            | CUSIP: N/A<br>LEI: N/A                        | Long             | EP               | CORP              | US        |   1920122 | NS      | $2188939.08   | 0.12%             |  |  |  | Yes           |                  3 | On Loan: No      |
| NUVALENT INC                              | NUVALENT INC-A                                  | CUSIP: 670703107<br>LEI: N/A                  | Long             | EC               | CORP              | US        |    412264 | NS      | $41341833.92  | 2.17%             |  |  |  | No            |                  1 | On Loan: No      |

### Signature

**Date Signed:** 2026-05-30

**Name of Applicant:** Stacie M. Smith

**Signature:** Stacie M. Smith

**Name of Signer:** Stacie M. Smith

**Title:** President and Treasurer